SGLT-2is Edge GLP-1 RAs on Foot Disease Danish target trial emulation finds modest neuropathy benefit emerging following year 3, but high discontinuation rates complicate causal interpretation By Kerri Miller January 5, 2026 5 min Conexiant Share Summary Takeaways Listen Insight Report Clinical Scorecard Quiz Poll Top Institutions Top Thought Leaders Top Thought Leaders in Pathology Brief introduction explaining scope and methodology. #1 Kathryn Wighton Editor • Conexiant #2 Andrea Surnit Editor • Conexiant #3 Kerri Miller Editor • Conexiant #4 Conexiant News Staff News Staff • Conexiant #5 Henry Thomas The Analytical Scientist #6 Jess Allerton Editor • Conexiant #7 Olivia Anderson ADA News #8 Julia Cipriano, MS, CMPP The ASCO Post #9 Doug Brunk #10 Jessica Allerton
